Literature DB >> 6208466

Bleomycin pulmonary toxicity: its relationship to renal dysfunction.

A G Dalgleish, R L Woods, J A Levi.   

Abstract

Two hundred seventy-five patients who had received bleomycin were examined for evidence of pulmonary toxicity. Twenty-six patients were diagnosed as having bleomycin pulmonary toxicity and, of these, 20 (77%) were documented as having renal dysfunction without other features recognized to be associated with the development of pulmonary toxicity. In this study renal dysfunction was a most important factor in the development of bleomycin pulmonary toxicity. As bleomycin is often administered with nephrotoxic drugs, it is suggested that renal function should be checked prior to each administration of bleomycin. It is proposed that appropriate dose modifications could significantly reduce the morbidity and mortality associated with bleomycin administration.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6208466     DOI: 10.1002/mpo.2950120503

Source DB:  PubMed          Journal:  Med Pediatr Oncol        ISSN: 0098-1532


  10 in total

1.  Prognostic impact of bleomycin pulmonary toxicity on the outcomes of patients with germ cell tumors.

Authors:  Yuki Maruyama; Takuya Sadahira; Yosuke Mitsui; Motoo Araki; Koichiro Wada; Ryuta Tanimoto; Yasuyuki Kobayashi; Masami Watanabe; Toyohiko Watanabe; Yasutomo Nasu
Journal:  Med Oncol       Date:  2018-04-26       Impact factor: 3.064

2.  Acute fibrinous and organising pneumonia: a rare histopathological variant of chemotherapy-induced lung injury.

Authors:  Arjun Gupta; Shiraj Sen; Harris Naina
Journal:  BMJ Case Rep       Date:  2016-04-06

3.  Development of acute lung injury after the combination of intravenous bleomycin and exposure to hyperoxia in rats.

Authors:  J G Hay; P L Haslam; A Dewar; B Addis; M Turner-Warwick; G J Laurent
Journal:  Thorax       Date:  1987-05       Impact factor: 9.139

Review 4.  Therapeutic drug monitoring in oncology. Problems and potential in antineoplastic therapy.

Authors:  M J Moore; C Erlichman
Journal:  Clin Pharmacokinet       Date:  1987-10       Impact factor: 6.447

Review 5.  Mechanisms of bleomycin-induced lung damage.

Authors:  J Hay; S Shahzeidi; G Laurent
Journal:  Arch Toxicol       Date:  1991       Impact factor: 5.153

Review 6.  Pharmacokinetic optimisation of anticancer therapy.

Authors:  J Liliemark; C Peterson
Journal:  Clin Pharmacokinet       Date:  1991-09       Impact factor: 6.447

7.  'JEB'--a carboplatin based regimen for malignant germ cell tumours in children.

Authors:  C R Pinkerton; V Broadbent; A Horwich; J Levitt; T J McElwain; S T Meller; M Mott; A Oakhill; J Pritchard
Journal:  Br J Cancer       Date:  1990-08       Impact factor: 7.640

Review 8.  Chemotherapy, targeted therapy and immunotherapy: Which drugs can be safely used in the solid organ transplant recipients?

Authors:  Umberto Maggiore; Alessandra Palmisano; Sebastiano Buti; Giulia Claire Giudice; Dario Cattaneo; Nicola Giuliani; Enrico Fiaccadori; Ilaria Gandolfini; Paolo Cravedi
Journal:  Transpl Int       Date:  2021-10-28       Impact factor: 3.842

9.  Fatal bleomycin pulmonary toxicity in the west of Scotland 1991-95: a review of patients with germ cell tumours.

Authors:  A B Simpson; J Paul; J Graham; S B Kaye
Journal:  Br J Cancer       Date:  1998-10       Impact factor: 7.640

Review 10.  Development of a best-practice clinical guideline for the use of bleomycin in the treatment of germ cell tumours in the UK.

Authors:  Robert A Watson; Hugo De La Peña; Maria T Tsakok; Johnson Joseph; Sara Stoneham; Jonathan Shamash; Johnathan Joffe; Danish Mazhar; Zoe Traill; Ling-Pei Ho; Sue Brand; Andrew S Protheroe
Journal:  Br J Cancer       Date:  2018-10-25       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.